Systemic treatment of advanced, metastatic, medullary thyroid carcinoma

Abstract

Medullary thyroid carcinoma (MTC) is a rare endocrine tumor, which arises from thyroid parafollicular C cells. Through its ability to metastasize by blood and lymphatic vessels, it can show a more aggressive clinical behavior than differentiated thyroid cancers. Mutation of RET gene is the main molecular alteration involved in MTC origin. In the case of germline RET mutation, MTC can be inherited in an autosomal dominant way and show three different phenotypes: familial medullary thyroid carcinoma and multiple endocrine neoplasia types IIA and IIB. In addition, in sporadic cases, somatic RET mutation remains the key molecular alteration in most of cases. Total thyroidectomy with prophylactic or therapeutic central compartment lymph nodes dissection is the surgical treatment of choice. Further surgical treatments and local therapies should be used in the case of single or few local or distant metastasis. However, in cases with large metastatic spread of the disease, particularly in those with significant tumor progression, additional systemic treatments are needed. In this review, we discuss the key points of systemic treatment in advanced, metastatic MTC. We provide an update on the main aspects (from biological rationale to clinical experience) of each treatment, focusing our attention on the drugs used in clinical practice in the last years. Finally, we give insights about the emerging treatments from highly selective RET inhibitors to new radionuclide therapy.

Keywords

Medullary thyroid carcinoma / tyrosine kinase inhibitors / targeted therapy / immunotherapy / radionuclide therapy / RET selective inhibitors

References

[1] Melvin KE.The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid.Proc Natl Acad Sci U S A1968;59:1216-22 PMCID:PMC224854

[2] Hazard JB,Crile G Jr.Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity.J Clin Endocrinol Metab1959;19:152-61

[3] Pacini F,Elisei R,Cola A.Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens.Am J Clin Pathol1991;95:300-8

[4] Gmunder-Lehner RB,Hedinger C.Distribution of C cells in the human thyroid gland.Schweiz Med Wochenschr1983;113:1385-94

[5] Available from: https://rarediseases.info.nih.gov/diseases/7004/thyroid-cancer-medullary. [Last accessed on 20 Apr 2021]

[6] Bergholm U,Telenius-Berg M,Wilander E.Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group.Acta Oncol1990;29:9-15

[7] Bhattacharyya N.A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.Otolaryngol Head Neck Surg2003;128:115-23

[8] Bondeson L.Occult thyroid carcinoma at autopsy in Malmö, Sweden.Cancer1981;47:319-23

[9] Christensen SB,Tibblin S.A clinical epidemiologic study of thyroid carcinoma in Malmö, Sweden.Curr Probl Cancer1984;8:1-49

[10] Romei C,Cetani F.Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.J Oncol2012;2012:705036 PMCID:PMC3503399

[11] Elisei R,Valerio L.Fifty years after the first description, MEN 2B syndrome diagnosis is still late: descriptions of two recent cases.J Clin Endocrinol Metab2019;104:2520-6

[12] Sanso GE,Garcia R.Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.Cancer2002;94:323-30

[13] Niccoli-Sire P,Baudin E.Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC).Eur J Endocrinol1999;141:468-74

[14] Machens A,Hoegel J.Early malignant progression of hereditary medullary thyroid cancer.N Engl J Med2003;349:1517-25

[15] Elisei R,Ramone T.Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations.Genes (Basel)2019;10:698 PMCID:PMC6771015

[16] Donis-Keller H,Chi D.Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.Hum Mol Genet1993;2:851-6

[17] Mulligan LM,Robinson BG.Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.J Intern Med1995;238:343-6

[18] Mulligan LM,Healey CS.Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.Nature1993;363:458-60

[19] Romei C,Elisei R.A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.Nat Rev Endocrinol2016;12:192-202

[20] Ciampi R,Ramone T.Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing.iScience2019;20:324-36 PMCID:PMC6817656

[21] Elisei R,Romei C.Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.J Clin Endocrinol Metab2008;93:682-7

[22] Molinaro E,Biagini A.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Nat Rev Endocrinol2017;13:644-60

[23] Christensen SB.Mortality from thyroid carcinoma in malmö, Sweden 1960–1977. A clinical and pathologic study of 38 fatal cases.Cancer1984;54:1629-34

[24] Kwon H,Sung TY.Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.J Surg Oncol2016;113:152-8

[25] Torresan F,Cavedon E.Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.Langenbecks Arch Surg2019;404:411-9

[26] Torresan F,Mian C.Long-term outcome after surgery for medullary thyroid carcinoma: a single-center experience.World J Surg2018;42:367-75

[27] Brierley J,Simpson WJ,Sutcliffe S.Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control.Thyroid1996;6:305-10

[28] Mathiesen JS,Vestergaard P.Survival and long-term biochemical cure in medullary thyroid carcinoma in denmark 1997-2014: a nationwide study.Thyroid2019;29:368-77 PMCID:PMC6437622

[29] Gharib H,Tiegs RD.Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970.Mayo Clinic Proceedings1992;67:934-40

[30] Matrone A,Prete A.Impact of advanced age on the clinical presentation and outcome of sporadic medullary thyroid carcinoma.Cancers (Basel)2020;13:94 PMCID:PMC7795457

[31] Kebebew E,Siperstein AE,Clark OH.Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.Cancer2000;88:1139-48

[32] Moley JF.Medullary thyroid carcinoma: management of lymph node metastases.J Natl Compr Canc Netw2010;8:549-56

[33] Romei C,Fugazzola L.Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.Eur J Endocrinol2010;163:301-8

[34] Elisei R.Routine serum calcitonin measurement in the evaluation of thyroid nodules.Best Pract Res Clin Endocrinol Metab2008;22:941-53

[35] Wells SA Jr,Dralle H.Revised american thyroid association guidelines for the management of medullary thyroid carcinoma.Thyroid2015;25:567-610 PMCID:PMC4490627

[36] Valerio L,Giani C.Targeted therapy in thyroid cancer: state of the art.Clin Oncol (R Coll Radiol)2017;29:316-24

[37] Viola D.Management of medullary thyroid cancer.Endocrinol Metab Clin North Am2019;48:285-301

[38] Schlessinger J.Cell signaling by receptor tyrosine kinases.Cell2000;103:211-25

[39] Lemmon MA.Cell signaling by receptor tyrosine kinases.Cell2010;141:1117-34 PMCID:PMC2914105

[40] Bible KC.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Nat Rev Clin Oncol2016;13:403-16

[41] Druker BJ,Resta DJ.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med2001;344:1031-7

[42] Tacconi EMC,Protheroe A.Review of adjuvant therapies in renal cell carcinoma: evidence to date.Onco Targets Ther2020;13:12301-16 PMCID:PMC7721274

[43] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[44] Matrone A,Pieruzzi L.Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life.Best Pract Res Clin Endocrinol Metab2017;31:319-34

[45] Brose MS,Jarzab B.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.Lancet2014;384:319-28 PMCID:PMC4366116

[46] Schlumberger M,Wirth LJ.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.N Engl J Med2015;372:621-30

[47] Gotink KJ.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?.Angiogenesis2010;13:1-14 PMCID:PMC2845892

[48] Posner I,Gazit A.Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.Mol Pharmacol1994;45:673-83

[49] Viola D,Molinaro E.Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.Endocr Relat Cancer2016;23:R185-205

[50] Fagin JA.Biologic and clinical perspectives on thyroid cancer.N Engl J Med2016;375:1054-67 PMCID:PMC5512163

[51] Eng C,Mulligan LM.Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.Hum Mol Genet1994;3:237-41

[52] Krampitz GW.RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.Cancer2014;120:1920-31

[53] Wells SA Jr,Robinson BG.Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.J Clin Endocrinol Metab2013;98:3149-64 PMCID:PMC5399478

[54] Raue F,Frank-Raue K.Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center.J Clin Endocrinol Metab2019;104:4264-72

[55] Romei C,Tacito A.New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.J Med Genet2016;53:729-34

[56] Agrawal N,Sausen M.Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.J Clin Endocrinol Metab2013;98:E364-9 PMCID:PMC3565108

[57] de Groot JW,van Ufford-Mannesse PQ.A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.J Clin Endocrinol Metab2007;92:3466-9

[58] Cohen EE,Vokes EE.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.J Clin Oncol2008;26:4708-13 PMCID:PMC4859206

[59] Schlumberger MJ,Bastholt L.Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.J Clin Oncol2009;27:3794-801

[60] Lam ET,Kloos RT.Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.J Clin Oncol2010;28:2323-30 PMCID:PMC2881718

[61] Carr LL,Goulart BH.Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.Clin Cancer Res2010;16:5260-8 PMCID:PMC3063514

[62] Bible KC,Molina JR.A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.J Clin Endocrinol Metab2014;99:1687-93 PMCID:PMC4010705

[63] De Falco V,Muthu M.Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.J Clin Endocrinol Metab2013;98:E811-9

[64] Schlumberger M,Cabanillas ME.A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer.Clin Cancer Res2016;22:44-53

[65] Sun Y,Gao M.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer.Thyroid2018;28:1455-61

[66] Wells SA Jr,Gagel RF.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.J Clin Oncol2012;30:134-41 PMCID:PMC3675689

[67] Elisei R,Müller SP.Cabozantinib in progressive medullary thyroid cancer.J Clin Oncol2013;31:3639-46 PMCID:PMC4164813

[68] Wedge SR,Dukes M.ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.Cancer Res2002;62:4645-55

[69] Carlomagno F,Guida T.ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Cancer Res2002;62:7284-90

[70] Kreissl MC,Elisei R.Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial.J Clin Oncol2020;38:2773-81 PMCID:PMC7430220

[71] Massicotte MH,Claude-Desroches M.Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.Eur J Endocrinol2014;170:575-82

[72] Chougnet CN,Leboulleux S.Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.Thyroid2015;25:386-91

[73] Ramos HE,Berdelou A.Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.Endocrine2021;71:434-42

[74] Valerio L,Matrone A.Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.Endocr Relat Cancer2020;27:97-110

[75] Trotti A,Setser A.Patient-reported outcomes and the evolution of adverse event reporting in oncology.J Clin Oncol2007;25:5121-7

[76] Wirth LJ,Robinson B.Efficacy of Selpercatinib in RET-altered thyroid cancers.N Engl J Med2020;383:825-35

[77] Hu M,Wirth LJ.Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC).Ann Oncol2020;31:S1084

[78] Hu MI,Dedecjus M.Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.Endocr Relat Cancer2019;26:241-50

[79] Fox E,Chuk MK.Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clin Cancer Res2013;19:4239-48 PMCID:PMC4274128

[80] Paepegaey AC,Louiset E.Long-term control of hypercortisolism by vandetanib in a case of medullary thyroid carcinoma with a somatic RET mutation.Thyroid2017;27:587-90

[81] Pitoia F,Schmidt A,Cross G.Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Arch Endocrinol Metab2015;59:343-6

[82] Nella AA,Fox E.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.J Clin Endocrinol Metab2014;99:3055-9 PMCID:PMC4154103

[83] Baudry C,Groussin L.Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.N Engl J Med2013;369:584-6

[84] Cabanillas ME,Jimenez C.Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond.Endocr Rev2019;40:1573-604 PMCID:PMC7341904

[85] Kurzrock R,Ball DW.Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.J Clin Oncol2011;29:2660-6 PMCID:PMC3646303

[86] Sherman SI,Elisei R.Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.Cancer2016;122:3856-64

[87] Schlumberger M,Müller S.Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.Ann Oncol2017;28:2813-9 PMCID:PMC5834040

[88] Eisenhauer EA,Bogaerts J.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009;45:228-47

[89] Massicotte MH,Broutin S.Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.J Clin Endocrinol Metab2013;98:2401-8

[90] Cabanillas ME,Jimenez C.Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.J Clin Endocrinol Metab2014;99:4390-6 PMCID:PMC4255127

[91] Brose MS,Chow LQM.Management of treatment-related toxicities in advanced medullary thyroid cancer.Cancer Treat Rev2018;66:64-73

[92] Cappagli V,Bonadio AG.Proteinuria is a late-onset adverse event in patients treated with cabozantinib.J Endocrinol Invest2021;44:95-103

[93] Basolo A,Elisei R.Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.Semin Cancer Biol2021;S1044-579X(20)30268

[94] Blevins DP,Hu M.Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.Thyroid2014;24:918-22 PMCID:PMC4026371

[95] Carlomagno F,Anaganti S.Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.Oncogene2004;23:6056-63

[96] Arao T,Furuta K.Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.Anticancer Res2011;31:2787-96

[97] Liu X,Mooers BHM,Wu J.Drug resistance profiles of mutations in the RET kinase domain.Br J Pharmacol2018;175:3504-15 PMCID:PMC6086982

[98] Tate JG,Jubb HC.COSMIC: the catalogue of somatic mutations in cancer.Nucleic Acids Res2019;47:D941-7 PMCID:PMC6323903

[99] Moura MM,Pinto AE.Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.Br J Cancer2009;100:1777-83 PMCID:PMC2695700

[100] Kohno T,Nakaoku T.REToma: a cancer subtype with a shared driver oncogene.Carcinogenesis2020;41:123-9

[101] Subbiah V,Tuch BB.Selective RET kinase inhibition for patients with RET-altered cancers.Ann Oncol2018;29:1869-76 PMCID:PMC6096733

[102] Subbiah V,Rahal R.Precision targeted therapy with BLU-667 for RET-driven cancers.Cancer Discov2018;8:836-49

[103] Seoane J.The right compound for the right target: tackling RET.Ann Oncol2018;29:1623-5

[104] Solomon BJ,Lin JJ.RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies.J Thorac Oncol2020;15:541-9 PMCID:PMC7430178

[105] Subbiah V,Terzyan SS.Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Ann Oncol2021;32:261-8 PMCID:PMC7883646

[106] Lin JJ,McCoach CE.Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Ann Oncol2020;31:1725-33

[107] Rosen EY,Clifford SE.Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.Clin Cancer Res2021;27:34-42 PMCID:PMC8009613

[108] Drilon AE,Rogers E.The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.J Clin Oncol2020;38:3616

[109] Egeblad M,Weaver VM.Dynamic interplay between the collagen scaffold and tumor evolution.Curr Opin Cell Biol2010;22:697-706 PMCID:PMC2948601

[110] McAllister SS.The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.Nat Cell Biol2014;16:717-27 PMCID:PMC6220424

[111] Hanahan D.Accessories to the crime: functions of cells recruited to the tumor microenvironment.Cancer Cell2012;21:309-22

[112] Velcheti V.Basic overview of current immunotherapy approaches in cancer.Am Soc Clin Oncol Educ Book2016;35:298-308

[113] Cunha LL,Morari EC.Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.Endocr Relat Cancer2013;20:103-10

[114] Bastman JJ,Zhu Y.Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer.J Clin Endocrinol Metab2016;101:2863-73 PMCID:PMC4929840

[115] Angell TE,Jang JK,LoPresti JS.BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Thyroid2014;24:1385-93 PMCID:PMC4148060

[116] Chowdhury S,Jessa F.Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.Oncotarget2016;7:32318-28 PMCID:PMC5078015

[117] Ahn S,Kim SW.Comprehensive screening for PD-L1 expression in thyroid cancer.Endocr Relat Cancer2017;24:97-106

[118] Mehnert JM,Brose MS.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.BMC Cancer2019;19:196 PMCID:PMC6399859

[119] Rocklin RE,Feldman Z.Cellular immune responses in familial medullary thyroid carcinoma.N Engl J Med1977;296:835-8

[120] George JM,Almoney R.Medullary carcinoma of the thyroid.cellular immune response to tumor antigen in a heritable human cancer.Cancer1975;36:1658-61

[121] Bilusic M,Arlen PM.Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Cancer Immunol Immunother2014;63:225-34 PMCID:PMC3944709

[122] Schott M,Klucken M,Scherbaum WA.Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination.Cancer Immunol Immunother2002;51:663-8

[123] Bachleitner-Hofmann T,Hassler M.Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.Oncol Rep2009;21:1585-92

[124] Bongiovanni M,Saglietti C.Very low expression of PD-L1 in medullary thyroid carcinoma.Endocr Relat Cancer2017;24:L35-8 PMCID:PMC5457503

[125] Bi Y,Bai X.PD-1/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population.Eur J Surg Oncol2019;45:353-8

[126] Pozdeyev N,Zhang L.Comprehensive immune profiling of medullary thyroid cancer.Thyroid2020;30:1263-79 PMCID:PMC7869888

[127] Shi X,Tan LC.Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study.J Clin Endocrinol Metab2021;106:120-32

[128] Shi X,Lei BW.Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma.Thyroid2019;29:1269-78

[129] Castellone MD.RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).Endocr Relat Cancer2018;25:T105-19

[130] Faggiano A,Pezzullo L.Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.Endocr Relat Cancer2009;16:225-31

[131] De Luca S,Camera L.Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.Ann Nucl Med2016;30:234-41

[132] Mato E,Chico A.Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma.J Clin Endocrinol Metab1998;83:2417-20

[133] Baudin E,Schlumberger M.Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.J Nucl Med1996;37:912-6

[134] Yamaga LYI,Campos Neto GC.⁶⁸Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with ¹¹¹In-octreotide SPECT/CT and conventional imaging.Eur J Nucl Med Mol Imaging2017;44:1695-701

[135] Bodei L,Grana C.Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.Cancer Biother Radiopharm2004;19:65-71

[136] Satapathy S,Sood A,Panda N.Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.Nucl Med Commun2020;41:629-35

[137] Parghane RV,Talole S.Clinical utility of ¹⁷⁷Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity.Head Neck2020;42:401-16

[138] DeGroot LJ.Management of thyroid nodules: how far have we come?.Hosp Pract (Off Ed)1986;21:9-10

[139] Lapa C,Schmid JS.Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy.Nucl Med Biol2015;42:349-54

[140] Vaisman F,Lopes FP.Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?.Clin Nucl Med2015;40:123-7

[141] Gao Z,Ezziddin S,An R.The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.J Cancer Res Clin Oncol2004;130:649-56

[142] Bodei L,Zoboli S.Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.Eur J Nucl Med Mol Imaging2003;30:207-16

[143] Paganelli G,Cremonesi M.Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.Eur J Nucl Med2001;28:426-34

[144] Pasieka JL,Rorstad O.The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.Surgery2004;136:1218-26

[145] Buscombe JR,Hilson AJ.Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.J Nucl Med2003;44:1-6

[146] Valkema R,Bakker WH.Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience.Semin Nucl Med2002;32:110-22

[147] Iten F,Schindler C.Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.Clin Cancer Res2007;13:6696-702

[148] Beukhof CM,van Nederveen FH.Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.BMC Cancer2019;19:325 PMCID:PMC6451300

[149] Behr TM.Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.Semin Nucl Med2002;32:97-109